Literature DB >> 26909716

Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.

Carl Diedrich Schlenkhoff1, Florian Gaertner, Markus Essler, Matthias Schmidt, Hojjat Ahmadzadehfar.   

Abstract

A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe bone marrow depression during Ra radionuclide therapy. Because of this, he was treated with Lu-PSMA in compassionate use for this not-yet-approved therapy. At the beginning of Lu-PSMA therapy, repeated blood transfusions (BT) were necessary. Six months after the last BT, after 3 cycles of Lu-PSMA, his blood count stabilized. He required no further BTs and his PSA level remained lowered.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26909716     DOI： 10.1097/RLU.0000000000001195

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  8 in total

1.  Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.

Authors:  Hojjat Ahmadzadehfar; Simone Wegen; Anna Yordanova; Rolf Fimmers; Stefan Kürpig; Elisabeth Eppard; Xiao Wei; Carl Schlenkhoff; Stefan Hauser; Markus Essler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-09       Impact factor: 9.236

2.  The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.

Authors:  Anna Yordanova; Anja Becker; Elisabeth Eppard; Stefan Kürpig; Christian Fisang; Georg Feldmann; Markus Essler; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-23       Impact factor: 9.236

Review 3.  PSMA PET and Radionuclide Therapy in Prostate Cancer.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter L Choyke
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

4.  Dosimetric Analysis of the Short-Ranged Particle Emitter 161Tb for Radionuclide Therapy of Metastatic Prostate Cancer.

Authors:  Peter Bernhardt; Johanna Svensson; Jens Hemmingsson; Nicholas P van der Meulen; Jan Rijn Zeevaart; Mark W Konijnenberg; Cristina Müller; Jon Kindblom
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

5.  Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.

Authors:  Hojjat Ahmadzadehfar; Stephan Schlolaut; Rolf Fimmers; Anna Yordanova; Stefan Hirzebruch; Carl Schlenkhoff; Florian C Gaertner; Zool Hilmi Awang; Stefan Hauser; Markus Essler
Journal:  Oncotarget       Date:  2017-10-07

Review 6.  PSMA Theranostics: Current Status and Future Directions.

Authors:  Kambiz Rahbar; Ali Afshar-Oromieh; Hossein Jadvar; Hojjat Ahmadzadehfar
Journal:  Mol Imaging       Date:  2018 Jan-Dec       Impact factor: 4.488

7.  Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer.

Authors:  Florian C Gaertner; Khalil Halabi; Hojjat Ahmadzadehfar; Stefan Kürpig; Elisabeth Eppard; Charalambos Kotsikopoulos; Nikolaos Liakos; Ralph A Bundschuh; Holger Strunk; Markus Essler
Journal:  Oncotarget       Date:  2017-07-06

8.  Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.

Authors:  Hojjat Ahmadzadehfar; Stefanie Zimbelmann; Anna Yordanova; Rolf Fimmers; Stefan Kürpig; Elisabeth Eppard; Florian C Gaertner; Xiao Wei; Stefan Hauser; Markus Essler
Journal:  Oncotarget       Date:  2017-02-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.